Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 22, Pages 4849-4860Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-1564
Keywords
-
Categories
Funding
- LaCaixa Foundation [100010434]
- Instituto de Salud Carlos III [PI17/01527]
- European Regional Development Fund (ERDF)
- [LCF/BQ/DR21/11880015]
Ask authors/readers for more resources
Immunotherapy has revolutionized the treatment of endometrial cancer by targeting different molecular subtypes and tumor microenvironment features.
Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair deficient tumors, pembrolizumab for tumors with high mutational load, and, more recently, pembrolizumab/lenvatinib for all patients with endometrial cancer. Endometrial cancer is a heterogeneous disease with distinct molecular subtypes and different prognoses. Differences between molecular subgroups regarding antigenicity and immunogenicity should be relevant to develop more tailored immunotherapeutic approaches. In this review, we aim to summarize and discuss the current evidence-Facts, and future opportunities-Hopes-of immunotherapy for endometrial cancer, focusing on relevant molecular and tumor microenvironment features of The Cancer Genome Atlas endometrial cancer subtypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available